mylab.pearson.com nework Question 5, Problem 11-16 (similar Part 2 of 5 (Real options and capital budgeting) You have come up with a great idea for a Tex-Mex-Th outlay will be \( \$ 5.9 \) million. You also estimate that there is a 50 percent chance that this new forever (a perpetuity), while there is a 50 percent chance of it producing a cash flow of only a. What is the NPV of the restaurant if the required rate of return you use to discount the pr b. What are the real options that this analysis may be ignoring? c. Explain why the project may be worthwhile even though you have just estimated that its a. Assume the required rate of return you use to discount the project cash flows is \( 12 \% \). Wh \$ 433333 (Round to the nearest dollar.) What is the NPV of the restaurant if things go poorly? \$ \( \square \) (Round to the nearest dollar.)
Added by Ismael M.
Close
Step 1
- Initial outlay: $5.9 million - Cash flow if successful: $433,333 (perpetuity) - Cash flow if unsuccessful: $0 - Probability of success: 50% - Probability of failure: 50% - Required rate of return: 12% Show more…
Show all steps
Your feedback will help us improve your experience
Derrick Danso and 54 other Principles of Accounting educators are ready to help you.
Ask a new question
Labs
Want to see this concept in action?
Explore this concept interactively to see how it behaves as you change inputs.
Recommended Videos
A 5-year project will require an investment of $100 million. This comprises of plant and machinery worth $80 million and a net working capital of $20 million. The entire outlay will be incurred at the project’s commencement. Financing for the project has been arranged as follows: 80,000 new common shares are issued, the market price of which is $500 per share. These shares will offer a dividend of $4 per share in year 1, which is expected to grow at a rate of 9% per year for an indefinite tenure. Remaining funds are borrowed by issuing 5-year, 9% semi-annual bonds, each bond having a face value of $1,000. These bonds now have a market value of $1,150 each. At the end of 5 years, fixed assets will fetch a net salvage value of $30 million, whereas the net working capital will be liquidated at its book value. The project is expected to increase revenues of the firm by $120 million per year. Expenses, other than depreciation, interest and tax, will amount to $80 million per year. The firm is subject to a tax rate of 30% Plant and machinery will be depreciated at the rate of 25% per year as per the written-downvalue method. You are required to: 1. Compute the cost of equity for this project 2. Compute the relevant cost of debt for this project. 3. Compute the WACC 4. Determine the initial cash flow for the project. 5. Determine the earnings before taxes for years 1 through 5 6. Compute the OCF for years 1 through 5 7. Compute the Terminal cash flow. 8. Compute the FCF for years 1 through 5 9. Compute the project’s NPV and IRR 10. Should the project be accepted or rejected?
Rabia S.
A new diesel generator with 18 MVA capacity must be purchased at the beginning of year 1. The cost of maintaining a generator i years old, and the cost of purchasing a new generator with same capacity at the beginning of each year are given in tables below. There is no trade-in value when a generator is replaced. Your goal is to minimize the total cost of having a diesel generator with 18 MVA capacity for five years. Determine the years in which a new generator should be purchased, and calculate the minimum cost. Solve using model only Year | Purchase cost ($) ---|--- 1 | 110000 2 | 120000 3 | 135000 4 | 150000 5 | 170000 Age of generator (i) | Maintenance cost for next year ($) ---|--- 0 | 30000 1 | 50000 2 | 80000 3 | 120000 4 | 180000
Shaiju T.
While Sunesis had sufficient capital to fund the original Phase-III design of the trial, the company was seeking an additional $25 million to fund a potential expansion of the study based on the results of an interim analysis. At that time, an independent data safety monitoring board (DSMB) would decide whether to stop the study early for efficacy or futility, continue the study as planned, or implement a one-time increase in sample size with an additional 225 patients. By designing the study this way, Sunesis could avoid conducting an unnecessarily large trial in certain cases, potentially reducing the overall cost and risk of their study. After conducting its due diligence, Royalty Pharma conditionally agreed to pay Sunesis the $25 million to acquire a royalty interest on the future net sales of Vosaroxin. However, under the terms of the agreement, Royalty Pharma would only invest the $25 million if, following the interim analysis, the study was stopped early for efficacy or if the sample-size increase was implemented. In return, assume Royalty Pharma would get a 3.6% royalty interest on future net sales of the drug if the study was stopped early for efficacy, or a 6.75% royalty on future net sales if the sample size was increased. Assume these scenarios were estimated to occur with probability 10% and 40%, respectively. Furthermore, the probability that the study would be terminated early for futility and abandoned was estimated to be 5%. If the sample size was increased, Royalty Pharma estimated there was a 10% chance the therapy would show a strong effect, a 65% chance that it would show a weak effect, and a 25% chance that it would show no effect and be abandoned. Finally, if the DSMB decided that the trial should continue as planned, Royalty Pharma would have the option of making the $25 million investment upon the un-blinding of the study (i.e., the results were made known) in exchange for a 3.6% royalty interest on future net sales. Given this scenario, Royalty Pharma estimated there was a 15% chance the therapy would show a strong effect, a 60% chance that it would show a weak effect, and a 25% chance that it would show no effect and be abandoned. As such, Royalty Pharma would be able to significantly limit its exposure to the risk of an undesirable outcome of the clinical trial and, at the same time, position itself to receive a sizable royalty in the event that Vosaroxin was approved. Vosaroxin was projected to be highly profitable, especially if the trial was stopped early for efficacy. Under this scenario, future net sales were projected to have a present value of $4 billion. If, however, the trial required a sample-size increase, then future net sales were projected to have a present value of only $2.5 billion under the strong effect scenario, and $0.5 billion under the weak effect scenario. Finally, if the DSMB decided that the trial should continue as planned, the future net sales would have a present value of $3 billion under the strong effect scenario, and $0.5 billion under the weak effect scenario. SOLVE FULL PROBLEM Build a decision tree for Royalty Pharma that shows the cash flows and probabilities of each possible scenario. Your tree should have 8 outcomes with 3 failures and 5 successes. What is the probability that the clinical trial fails and the project is abandoned? (Note: Your answer should be a number in percentage form. Do not enter '%'.) Hint: Remember that the probabilities leaving a branch must sum to 100%. ____% What is Vosaroxin's rNPV from Royalty Pharma's perspective? For simplicity, assume the discount rate is 0% so the specific timing of the various cash flows can be ignored. (Note: Your answer should be expressed in units of millions of dollars.) $____MILLION
Patha S.
Recommended Textbooks
Horngren’s Cost Accounting
Cost Accounting A Managerial Emphasis
Principles of Accounting Volume 1: Financial Accounting
18,000,000+
Students on Numerade
Trusted by students at 8,000+ universities
Watch the video solution with this free unlock.
EMAIL
PASSWORD